Thursday, September 26, 2013 1:24:38 PM
ONVO daily/weekly charts + profile: 3D bioprinting play with massive potential. Pfizer, La Roche, Michale J Fox foundation, etc are development partners... Their first product (Liver Assays) is due to launch in 2014, which imo will dramatically alter drug development forever.
Organovo Holdings, Inc. develops three-dimensional (3D) bioprinting technology for creating functional human tissues on demand for research and medical applications. The company?s 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting research and development. The company was founded in 2007 and is based in San Diego, California.
Organovo Holdings, Inc. develops three-dimensional (3D) bioprinting technology for creating functional human tissues on demand for research and medical applications. The company?s 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting research and development. The company was founded in 2007 and is based in San Diego, California.
The Graphene, Graphite and Carbon Nanotube Research Board... Profit on the future...
http://investorshub.advfn.com/boards/board.aspx?board_id=24137
My postings contain many opinions. So please do your own
research and validation.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
